{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"18.5","value":"5.6"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"5.1","value":"3.9"},{"comment":"Not estimable due to low number of events","groupId":"OG002","lowerLimit":"1.9","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to low number of events","groupId":"OG003","lowerLimit":"0.4","upperLimit":"NA","value":"12.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"Among participants who had a response of CR, CRi, CRp, PR, mCR, or MLFS based on the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS, assessed by the Investigator, duration of response was calculated from the date of the first occurrence of response to the date of documented disease relapse, progression, or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method. Participants without relapse, progressive disease, or death due to any cause were censored at the date of the last adequate response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants ≥ 60 years old with relapsed, refractory AML or participants of any age if relapsed post-bone marrow transplant (BMT) received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 1 Dose Expansion Arm 1: Enasidenib 100 mg QD"},{"description":"Participants \\< 60 years old with R/R AML, excluding participants who relapsed post-BMT, received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG001","title":"Phase 1 Dose Expansion Arm 2: Enasidenib 100 mg QD"},{"description":"Untreated AML participants ≥ 60 years old who declined standard of care received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG002","title":"Phase 1 Dose Expansion Arm 3: Enasidenib 100 mg QD"},{"description":"Participants with advanced hematologic malignancies not eligible for Arms 1 to 3 received 100 mg enasidenib QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG003","title":"Phase 1 Dose Expansion Arm 4: Enasidenib 100 mg QD"}],"paramType":"MEDIAN","populationDescription":"Participants who received at least one dose of study treatment in Phase 1 Dose Expansion with an objective response.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment to the data cut-off date of 01 September 2017; overall median time on follow-up in Phase 1 Dose Expansion was 8.3 months (range 0.5 to 32.8 months).","title":"Phase 1 Dose Expansion: Kaplan-Meier Estimate of Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}